Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye
Retrieved on:
Wednesday, October 20, 2021
Software, Research, Pharmaceutical, Optical, Consumer, Technology, Clinical Trials, Science, Children, Audio, Video, FDA, Other Technology, Health, Safety, Virtual reality, MD, Compliance, HMD, Technology, Amblyopia, Strabismus, Myopia, American Academy, Ageing, Anisometropia, Patient, FDA, Astigmatism, Atropine, Food, Cleveland, VR, Cataract, Picower Institute for Learning and Memory, Eye, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Visual acuity, Brain, Hospital, Randomized controlled trial, Cleveland Clinic, HMDS, Learning, Sesame Workshop, Severe cognitive impairment, MIT, LogMAR chart, Therapy, Doctor of Philosophy, Parent, De novo, Pharmacy, Far-sightedness, Memory, Physician, Pharmaceutical industry, Telescopic sight, Luminopia One, Amblyopia4, Luminopia, LUMINOPIA ONE, AMBLYOPIA4, LUMINOPIA
Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.
Key Points:
- Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.
- The FDA approval of a new digital therapy with robust clinical evidence for children affected by amblyopia is a major development.
- The idea of prescribing TV shows and movies to treat amblyopia in children instead of eye patches or eye drops is an exciting prospect.
- Luminopia One is the first FDA-approved digital therapeutic for a neuro-visual disorder in children, indicated to improve vision in children with amblyopia.